EP0271211A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Use of cartilage-inducing factor B (cif-B) for the manufacture of a medicament for inhibiting tumor growth
Assignee: Oncogen LP
•
Filing: 1987-11-06
•
Granted: —
•
Expires: 2007-11-06
Abstract
Abstract A polypeptide called cartilage-inducing factor B (CIF-B) or transforming growth factor beta 2 (TGF-β2) that is found in bone and has heretofore been identified as having in vitro cartilage-inducing activity, TGF-β activity, and anti-inflammatory activity has now been found to possess potent oncostatic activity. CIF-B showed oncostatic activity on human and animal tumors, including carcinomas, adenocarcinomas, lymphomas, and melanomas.
Inventors
- 👤 John M. Mcpherson
- 👤 Daniel R. Twardzik
- 👤 George J. Todaro
- 👤 Karl A. Piez
- 👤 Jane E. Ranchalis
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 03:08
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61P; A61P35/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/12
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
13 words
Use of CIF-B (TGF-β2) for the manufacture of a medicament for treating cancer.
Claim 2
Dependent Claim
13 words
Use of CIF-B (TGF-β2) for the manufacture of a medicament for treating cancer.
Claim 3
Dependent Claim
18 words
Use of CIF-B as in claim 1 wherein the CIF-B has the following partial N-terminal amino acid sequence:
Claim 4
Dependent Claim
20 words
The use of CIF-B as in claim 1 or 2 wherein the cancer is a carcinoma, adenocarcinoma, melanoma, or lymphoma.
Claim 5
Dependent Claim
18 words
The use of CIF-B as in claim 3 wherein the carcinoma is breast, lung, colon or ovarian carcinoma.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.